Rare diseases
Investigational molecules
Locations
Recruiting trials first
16 clinical trials in this condition
Bulgaria
Germany
France
RomaniaIn short
Understanding how chronic hepatitis B is diagnosed is the first step toward protecting your liver and your future. While this infection may not always announce itself with obvious symptoms, the right tests can reveal what's happening inside your body and help guide decisions that truly matter for your health.
If you've been told you might have chronic hepatitis B, or if you're wondering whether you should get tested, you're not alone. Many people discover this infection during routine blood work or screening, often without any warning signs. Chronic hepatitis B is a long-term liver infection caused by the hepatitis B virus, and it's defined as having the virus in your body for more than six months. What makes this condition particularly challenging is that many people feel perfectly healthy while carrying the virus, which is why it's sometimes called a "silent killer."
The Centers for Disease Control and Prevention recommends that all adults aged 18 years or older should be tested at least once during their lifetime for hepatitis B. However, certain groups of people need testing more urgently. If you were born in regions where hepatitis B is common—such as parts of Asia, Africa, South America, the Middle East, or the Caribbean—you should definitely get tested. The same applies if your parents were born in these areas, even if you were born elsewhere.
Pregnant women must be tested for hepatitis B at their first prenatal visit for each pregnancy, as this protects both mother and baby. People who inject drugs, those with multiple sexual partners, anyone living with or having sex with someone who has hepatitis B, and men who have sex with men are all at higher risk and should seek testing. Additionally, if you have certain health conditions like HIV, hepatitis C, kidney failure requiring dialysis, or chronic liver disease, testing is essential because these conditions can interact with hepatitis B in complex ways.
People taking medications that suppress the immune system, such as those used after organ transplants or for certain autoimmune conditions, should also be tested before starting treatment. The hepatitis B virus can reactivate when the immune system is weakened, causing serious complications. Even if you don't fit into any of these categories but have concerns about possible exposure to the virus through blood, medical procedures, or other means, speaking with your doctor about testing is a wise choice.
The diagnostic process begins with your healthcare provider asking detailed questions about your medical history and conducting a physical examination. During the exam, your provider will look for signs of liver damage, such as yellowing of your skin and the whites of your eyes, a condition called jaundice. They will also check for tenderness or pain in your abdomen, particularly in the upper right area where your liver is located. Other signs they might look for include swelling in your belly, arms, or legs caused by fluid buildup, which can indicate advanced liver disease.
Your doctor will ask about potential exposures to the virus, including whether you've shared needles, had unprotected sex with someone who might have hepatitis B, or received medical procedures in countries where infection control practices may be less rigorous. They'll also want to know if you've traveled to regions where hepatitis B is common, whether anyone in your family has the infection, and if you've ever received blood transfusions or organ transplants. This information helps them assess your risk and understand how you might have contracted the virus.
Blood tests are the most important tools for diagnosing chronic hepatitis B. These tests can detect the virus itself, measure your body's immune response, and determine whether your liver is being damaged. Several different blood tests work together to give a complete picture of your infection.
The first and most basic test looks for hepatitis B surface antigen (HBsAg). An antigen is a part of the virus that your body recognizes as foreign. If HBsAg is found in your blood, it means you currently have a hepatitis B infection. If this antigen remains detectable for longer than six months, the infection is considered chronic rather than acute. This single test can tell you whether you're carrying the virus, but it can't tell you how active the infection is or how much damage it's causing.
Your doctor will also test for antibodies, which are proteins your immune system makes to fight infections. The hepatitis B surface antibody (anti-HBs) test shows whether you've recovered from a past infection or have been successfully vaccinated. If you have these antibodies and no surface antigen, it means you're protected against future hepatitis B infections. Another antibody test looks for hepatitis B core antibody (anti-HBc), which indicates whether you've ever been exposed to the virus, even if you cleared the infection years ago.
The hepatitis B e antigen (HBeAg) test is another crucial measurement. When this antigen is present, it typically means the virus is actively reproducing in your body and you're highly contagious. People who are HBeAg-positive generally have higher levels of virus in their blood and are more likely to transmit the infection to others. Some people naturally clear the e antigen over time and develop antibodies against it, which is generally a good sign that the infection is becoming less active.
A viral load test, also called hepatitis B DNA or HBV DNA test, measures the actual amount of virus in your bloodstream. This test is crucial for determining how active your infection is and whether you need treatment. The viral load is measured in international units per milliliter (IU/mL). If your viral load is above 2,000 IU/mL when you're HBeAg-negative, or above 20,000 IU/mL when you're HBeAg-positive, your doctor may recommend starting antiviral medication. The goal of treatment is to reduce your viral load to undetectable levels, meaning the amount is so low that standard tests cannot measure it. However, undetectable does not mean cured—the virus remains in your body but at very low levels.
Your blood also contains substances that can reveal whether your liver is being damaged. Alanine aminotransferase (ALT) is an enzyme found inside liver cells. When liver cells are injured or dying, ALT leaks into your bloodstream, causing blood levels to rise. In general, normal ALT levels are around 35 IU/mL for men and 25 IU/mL for women, though these ranges can vary slightly between laboratories. Elevated ALT levels indicate that your liver is experiencing active damage, which may mean your immune system is fighting the virus and causing inflammation in the process.
Regular monitoring of both viral load and ALT levels is essential because these numbers can change over time. You might have low levels for years, only to see them rise later as the virus becomes more active. This is why people with chronic hepatitis B need to see their doctor for routine blood tests every six months, even when they feel perfectly healthy. These regular check-ups help catch changes early, when treatment can be most effective.
Beyond blood tests, imaging studies help doctors see the physical condition of your liver. A liver ultrasound uses sound waves to create pictures of your liver, allowing doctors to check for signs of damage, scarring, or tumors. This test is painless and involves moving a device called a transducer over your abdomen while you lie on an examination table. The sound waves bounce off your organs and create images on a screen.
A specialized type of ultrasound called transient elastography, commonly known by the brand name Fibroscan, can measure liver stiffness. A stiff liver often indicates the presence of fibrosis, which is scarring of the liver tissue. This test is particularly useful because it's non-invasive, meaning it doesn't require any needles or surgery. It gives doctors important information about how much damage the virus has caused and helps them decide whether treatment is needed.
In some situations, your doctor may recommend a liver biopsy, which involves removing a small sample of liver tissue for detailed examination under a microscope. During this procedure, your doctor inserts a thin needle through your skin and into your liver to extract a tiny piece of tissue. The sample is then analyzed by a specialist to determine the degree of inflammation and scarring.
While a liver biopsy provides very detailed information about liver damage, it's not needed for everyone. Many people can be accurately assessed using blood tests and imaging studies alone. Biopsies are typically reserved for cases where the diagnosis is unclear, when it's important to precisely determine the stage of liver disease, or when doctors need to rule out other causes of liver damage occurring alongside hepatitis B.
People with chronic hepatitis B face an increased risk of developing hepatocellular carcinoma, a type of liver cancer, even if they don't yet have cirrhosis. For this reason, regular screening for liver cancer is an essential part of managing chronic hepatitis B. Your doctor will likely order blood tests to measure alpha-fetoprotein (AFP), a protein that can be elevated when liver cancer is present. If AFP levels are high, additional blood tests or imaging studies will be done to investigate further.
Liver ultrasound scans are also used to screen for cancer by creating detailed images of the liver that can reveal tumors or suspicious areas. These screening tests are typically performed every six months for people with chronic hepatitis B, especially those with cirrhosis or other risk factors for cancer. Early detection of liver cancer dramatically improves treatment outcomes, making regular screening a potentially life-saving practice.
If you're considering participating in a clinical trial for new hepatitis B treatments, you'll need to undergo specific diagnostic tests that serve as standard criteria for enrollment. Clinical trials are research studies that test new medications or treatment approaches before they become widely available. These studies have strict requirements to ensure that participants are appropriate candidates and that results are scientifically valid.
Most clinical trials require confirmation of chronic hepatitis B infection through blood tests showing the presence of HBsAg for at least six months. Trials often specify minimum viral load levels, as new treatments are typically designed for people with active viral replication. You may need to have an HBV DNA level above a certain threshold, such as 2,000 IU/mL or 20,000 IU/mL, depending on whether you're HBeAg-positive or negative.
Clinical trials also assess liver function and damage using several measurements. Your ALT levels may need to fall within a specific range—high enough to indicate active liver inflammation but not so high that you're experiencing acute liver failure. Trials may require liver imaging studies or even biopsies to determine the stage of fibrosis or cirrhosis in your liver. Some trials are specifically designed for people with early-stage disease, while others focus on those with more advanced cirrhosis.
Additional testing may include checking for coinfections with other viruses like hepatitis C, hepatitis D, or HIV, as these can affect how you respond to treatment and may either qualify or disqualify you from certain trials. Blood tests to evaluate your kidney function, complete blood count, and overall health status are also standard. Clinical trials typically exclude pregnant or breastfeeding women due to potential risks to the baby, so pregnancy testing is required for women of childbearing age.
Some trials test combination therapies or novel approaches aimed at achieving a "functional cure," which means loss of HBsAg from the blood even without complete elimination of the virus from the liver. For these studies, baseline measurements of all viral markers become especially important for tracking response to treatment. Researchers need to document exactly where you're starting from so they can measure how much improvement occurs during the trial.
The outlook for people with chronic hepatitis B varies considerably depending on several factors. Most adults with hepatitis B recover fully from acute infection, even when symptoms are severe. However, the younger a person is when infected, the higher the likelihood of developing chronic infection. About 90% of infants who contract hepatitis B at birth will develop chronic infection, compared to 25-50% of children aged 1 to 5 years, and only about 5% of adults. This age-related difference makes it absolutely critical that babies receive the hepatitis B vaccine at birth to prevent infection in the first place.
Without antiviral treatment, the progression of chronic hepatitis B can be significant. The five-year cumulative incidence of developing cirrhosis—severe scarring of the liver—ranges from 8% to 20%. People who develop cirrhosis face a serious risk of their liver disease getting worse if they remain untreated. The progression isn't always steady; chronic hepatitis B can worsen slowly over decades, or it can deteriorate rapidly in some cases.
Several factors influence how the disease will progress. Having persistently elevated levels of HBV DNA in the blood increases the risk of liver damage. Men tend to have worse outcomes than women. Older age at the time of diagnosis, a family history of liver cancer, alcohol use, and coinfection with hepatitis D, hepatitis C, or HIV all worsen the prognosis. Additionally, infection with certain genotypes of the virus, particularly genotypes C and D, may be associated with more severe disease.
The good news is that antiviral treatment can dramatically improve outcomes. Treatment suppresses viral replication, decreases hepatic inflammation and fibrosis, and reduces the likelihood of serious clinical disease. Studies show that appropriate treatment for chronic hepatitis B can help prevent cirrhosis, liver cancer, and liver failure. For people who already have cirrhosis, treatment is especially important because it can slow or even reverse some of the scarring and significantly reduce the risk of complications.
Survival rates for people with chronic hepatitis B depend heavily on whether the disease has progressed to cirrhosis and whether treatment is received. People with chronic hepatitis B who haven't yet developed cirrhosis and who receive appropriate monitoring and treatment can expect to live long, healthy lives with near-normal life expectancy.
However, untreated chronic hepatitis B that progresses to advanced stages carries serious mortality risks. About 20% of people with chronic hepatitis B develop cirrhosis or liver cancer and may die prematurely from these complications. Once cirrhosis develops, particularly if it reaches the decompensated stage where the liver can no longer perform its essential functions, the outlook becomes much more serious. Five-year survival rates among people with untreated decompensated cirrhosis can be as low as 15%.
The World Health Organization estimates that in 2022, hepatitis B resulted in approximately 1.1 million deaths worldwide, mostly from cirrhosis and liver cancer. This underscores why early detection, regular monitoring, and timely initiation of treatment when needed are so critical. Screening for liver cancer every six months can improve survival dramatically because early-stage cancers are much more treatable. One study found that more than one-third of people with chronic hepatitis B lived significantly longer if they had six-monthly screening compared to no screening.
For people with both chronic hepatitis B and chronic hepatitis D coinfection, the prognosis is more concerning. If left untreated, this combination causes cirrhosis in up to 70% of affected people. However, even in these challenging cases, close medical supervision and appropriate treatment can help manage the disease and extend both the length and quality of life.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Patient organisations offering help, community and advocacy
Tell us about your condition – we search every trial in Europe and connect you with the right site.
